Literature DB >> 31768760

The Lotus Valve System: an In-depth Review of the Technology.

Matthew E Seigerman1, Ashwin Nathan1, Saif Anwaruddin2.   

Abstract

PURPOSE OF REVIEW: Innovation for transcatheter aortic valve replacement (TAVR) has transformed a medically complex treatment into a standardized procedure. While Edwards SAPIEN and Medtronic CoreValve occupy the market for TAVR in the United States (US), additional valve systems are being developed. The Boston Scientific Lotus Valve system was recently FDA-approved and will represent the third valve in the US market. This evidence-based review will summarize advantages, disadvantages, and projected impact of this new TAVR system. RECENT
FINDINGS: The Lotus Valve system demonstrates superiority in terms of rates of paravalvular leak, with similar rates of mortality and disabling stroke. This benefit is at the expense of increased pacemaker implantation rates, though preliminary data from subsequent iterations of the Lotus Valve suggest decreasing rates over time. There is much anticipation from ongoing trials utilizing the Lotus Edge system, which may perform best for those with pre-existing pacemakers or anatomy that increases likelihood of paravalvular leak.

Entities:  

Keywords:  Aortic stenosis; Device development; Lotus Valve; SAVR; TAVR

Mesh:

Year:  2019        PMID: 31768760     DOI: 10.1007/s11886-019-1234-5

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  37 in total

1.  Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients.

Authors:  Michael J Mack; Martin B Leon; Vinod H Thourani; Raj Makkar; Susheel K Kodali; Mark Russo; Samir R Kapadia; S Chris Malaisrie; David J Cohen; Philippe Pibarot; Jonathon Leipsic; Rebecca T Hahn; Philipp Blanke; Mathew R Williams; James M McCabe; David L Brown; Vasilis Babaliaros; Scott Goldman; Wilson Y Szeto; Philippe Genereux; Ashish Pershad; Stuart J Pocock; Maria C Alu; John G Webb; Craig R Smith
Journal:  N Engl J Med       Date:  2019-03-16       Impact factor: 91.245

2.  Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30-day primary endpoint results from the REPRISE II study.

Authors:  Ian T Meredith Am; Darren L Walters; Nicolas Dumonteil; Stephen G Worthley; Didier Tchétché; Ganesh Manoharan; Daniel J Blackman; Gilles Rioufol; David Hildick-Smith; Robert J Whitbourn; Thierry Lefèvre; Rüdiger Lange; Ralf Müller; Simon Redwood; Dominic J Allocco; Keith D Dawkins
Journal:  J Am Coll Cardiol       Date:  2014-09-30       Impact factor: 24.094

3.  5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial.

Authors:  Samir R Kapadia; Martin B Leon; Raj R Makkar; E Murat Tuzcu; Lars G Svensson; Susheel Kodali; John G Webb; Michael J Mack; Pamela S Douglas; Vinod H Thourani; Vasilis C Babaliaros; Howard C Herrmann; Wilson Y Szeto; Augusto D Pichard; Mathew R Williams; Gregory P Fontana; D Craig Miller; William N Anderson; Jodi J Akin; Michael J Davidson; Craig R Smith
Journal:  Lancet       Date:  2015-03-15       Impact factor: 79.321

4.  5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial.

Authors:  Michael J Mack; Martin B Leon; Craig R Smith; D Craig Miller; Jeffrey W Moses; E Murat Tuzcu; John G Webb; Pamela S Douglas; William N Anderson; Eugene H Blackstone; Susheel K Kodali; Raj R Makkar; Gregory P Fontana; Samir Kapadia; Joseph Bavaria; Rebecca T Hahn; Vinod H Thourani; Vasilis Babaliaros; Augusto Pichard; Howard C Herrmann; David L Brown; Mathew Williams; Jodi Akin; Michael J Davidson; Lars G Svensson
Journal:  Lancet       Date:  2015-03-15       Impact factor: 79.321

5.  Clinical outcomes at 1 year following transcatheter aortic valve replacement.

Authors:  David R Holmes; J Matthew Brennan; John S Rumsfeld; David Dai; Sean M O'Brien; Sreekanth Vemulapalli; Fred H Edwards; John Carroll; David Shahian; Fred Grover; E Murat Tuzcu; Eric D Peterson; Ralph G Brindis; Michael J Mack
Journal:  JAMA       Date:  2015-03-10       Impact factor: 56.272

6.  Permanent Pacemaker Implantation after TAVR - Predictors and Impact on Outcomes.

Authors:  Marcel Weber; Jan-Malte Sinning; Christoph Hammerstingl; Nikos Werner; Eberhard Grube; Georg Nickenig
Journal:  Interv Cardiol       Date:  2015-05

7.  Transcatheter aortic-valve replacement with a self-expanding prosthesis.

Authors:  David H Adams; Jeffrey J Popma; Michael J Reardon; Steven J Yakubov; Joseph S Coselli; G Michael Deeb; Thomas G Gleason; Maurice Buchbinder; James Hermiller; Neal S Kleiman; Stan Chetcuti; John Heiser; William Merhi; George Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; John Conte; Brijeshwar Maini; Mubashir Mumtaz; Sharla Chenoweth; Jae K Oh
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

8.  Transfemoral aortic valve implantation in pure native aortic valve insufficiency using the repositionable and retrievable lotus valve.

Authors:  Jochen Wöhrle; Christoph Rodewald; Wolfgang Rottbauer
Journal:  Catheter Cardiovasc Interv       Date:  2015-06-23       Impact factor: 2.692

9.  Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery.

Authors:  Jeffrey J Popma; David H Adams; Michael J Reardon; Steven J Yakubov; Neal S Kleiman; David Heimansohn; James Hermiller; G Chad Hughes; J Kevin Harrison; Joseph Coselli; Jose Diez; Ali Kafi; Theodore Schreiber; Thomas G Gleason; John Conte; Maurice Buchbinder; G Michael Deeb; Blasé Carabello; Patrick W Serruys; Sharla Chenoweth; Jae K Oh
Journal:  J Am Coll Cardiol       Date:  2014-03-19       Impact factor: 24.094

10.  Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.

Authors:  Martin B Leon; Craig R Smith; Michael J Mack; Raj R Makkar; Lars G Svensson; Susheel K Kodali; Vinod H Thourani; E Murat Tuzcu; D Craig Miller; Howard C Herrmann; Darshan Doshi; David J Cohen; Augusto D Pichard; Samir Kapadia; Todd Dewey; Vasilis Babaliaros; Wilson Y Szeto; Mathew R Williams; Dean Kereiakes; Alan Zajarias; Kevin L Greason; Brian K Whisenant; Robert W Hodson; Jeffrey W Moses; Alfredo Trento; David L Brown; William F Fearon; Philippe Pibarot; Rebecca T Hahn; Wael A Jaber; William N Anderson; Maria C Alu; John G Webb
Journal:  N Engl J Med       Date:  2016-04-02       Impact factor: 91.245

View more
  1 in total

1.  Redo Transcatheter Aortic Valve Implantation with the ALLEGRA Transcatheter Heart Valve: Insights from Bench Testing.

Authors:  Mariama Akodad; Maximilian Kütting; Stephanie Sellers; Alina Kirsten; Philipp Marx; Isabel Kim; Anson Cheung; Jonathon Leipsic; Lars Søndergaard; Stefan Toggweiler; David A Wood; John G Webb; Janarthanan Sathananthan
Journal:  Cardiovasc Eng Technol       Date:  2022-05-03       Impact factor: 2.495

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.